1-8 of 8
Hatice Savas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort

Frederique St-Pierre, Stephen Broski, Zequn Sun, Masha Kocherginsky, Andrew Quon, Lucia Baratto, Hatice Savas, Lale Kostakoglu, Jane N. Winter, Thomas E. Witzig, Brad S. Kahl, Andrew Matthew Evens, Leo I. Gordon
Journal: Blood
Blood (2022) 140 (Supplement 1): 6480–6481.
https://doi.org/10.1182/blood-2022-162114
Published: 2022
Journal Articles

Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis

Pamela Allen, Qing C Chen, Xinyan Lu, Kaitlyn O'Shea, Joan Chmiel, Madina Sukhanova, Liron Barnea Slonim, Hatice Savas, Eric Mou, Barbara Pro, Andrew M. Evens, Brett Alan Palmer, Ranjana Advani, Leo I. Gordon, Jane N. Winter
Journal: Blood
Blood (2021) 138 (Supplement 1): 231.
https://doi.org/10.1182/blood-2021-147042
Published: 2021
Journal Articles

Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial

Locke J. Bryan, Carla Casulo, Pamela Allen, Scott E. Smith, Hatice Savas, Reem Karmali, Barbara Pro, Kaitlyn O'Shea, Joan Chmiel, Brett Alan Palmer, Jayesh Mehta, Leo I. Gordon, Jane N. Winter
Journal: Blood
Blood (2021) 138 (Supplement 1): 229.
https://doi.org/10.1182/blood-2021-145111
Published: 2021
Journal Articles

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Clinical Trials & Observations
Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O’Shea, Leo I. Gordon, Jane N. Winter
Journal: Blood
Blood (2021) 137 (10): 1318–1326.
https://doi.org/10.1182/blood.2020007400
Published: 2021
Includes: Supplemental data
Journal Articles

PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy

Pamela B. Allen, MD MSc, Xinyan Lu, MD, Qing C Chen, MD PhD, Liron Barnea Slonim, MD, Madina Sukhanova, PhD, Hatice Savas, MD, Joan Chmiel, Kaitlyn O'Shea, Andrew M. Evens, DO,MMSc, Ranjana Advani, MD, Barbara Pro, MD, Reem Karmali, MDMSc, Brett Alan Palmer, BS, Jeffrey Bearden, BA, Eric Mou, MD, Gary Dillehay, MD, Leo I. Gordon, MD, Jane N. Winter, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-139816
Published: 2020
Journal Articles

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD

Pamela Allen, MD MSc, Hatice Savas, MD, Andrew M. Evens, DO,MSc, Barbara Pro, MD, Reem Karmali, MD, Brett Alan Palmer, BS, Eric Mou, MD, Jeffrey Bearden, BA, Denise M Scholtens, PhD, Gary Dillehay, MD, Leo I. Gordon, MD, Jane N. Winter, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 235.
https://doi.org/10.1182/blood-2019-123906
Published: 2019
Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4029.
https://doi.org/10.1182/blood-2019-123879
Published: 2019
Journal Articles

A Phase II Study of Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monotherapy with FDG-PET-Derived Metabolic Tumor Volume and Total Lesion Glycolysis

Hatice Savas, MD, Pamela Allen, MDMSc, Andrew M. Evens, DO, MSc, Barbara Pro, MD, Gary Dillehay, MD, Alfred Rademaker, PhD, Brett Alan Palmer, BS, Ranjana Advani, MD, Leo I. Gordon, MD, Jane N. Winter, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1651.
https://doi.org/10.1182/blood-2018-99-113836
Published: 2018